14
OCT
2010

Northwest Biotherapeutics To Present At Inaugural Cancer Immunotherapy Conference

Posted By :
Comments : Off
BETHESDA, Md., Oct. 14 — Northwest Biotherapeutics (OTC Bulletin Board: NWBO) today announced that the company will be presenting at the Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:00 p.m. EDT on October 21, 2010, at the New York Academy of Medicine in New York. Dr. Marnix Bosch, Chief Technical Officer, will provide an overview of the Company’s DCVax® technology and unprecedented...
Read More
03
AUG
2010

Long-Term Follow-Up Of DCVax®-Treated Brain Cancer Patients Shows 33% Of Patients Reached 4-Year Survival And 27% Have Reached Or Exceeded 6-Year Survival

Posted By :
Comments : Off
BETHESDA, MD – August 3, 2010 – Northwest Biotherapeutics, Inc. (“NWBT” or the “Company”) (OTCBB: NWBO) today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme (“GBM”), the most rapid and lethal type of brain cancer, were treated with NWBT’s DCVax®-Brain personalized immune therapy. The data through July 1, 2010, show that...
Read More
07
JUL
2010

Northwest Biotherapeutics Raises Funding And Proceeds With Balance Sheet Restructuring

Posted By :
Comments : Off
BETHESDA, MD – July 7, 2010 – Northwest Biotherapeutics, Inc. (“NWBT” or the “Company”) (OTCBB: NWBO), developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding of $2.65 million from investors. The funding included $1.75 million in purchases of restricted common stock of the Company (the “Common Stock”) by a number of private investors, together with purchases of restricted Common...
Read More
07
JUN
2010

Exceptional Survival Data, Lower Costs Key To The Competitive Advantage Of DCVax® – Northwest Biotherapeutics’ Vaccine For Multiple Cancers

Posted By :
Comments : Off
Comprehensive report by recognized Pharma and Biotech Analyst Dr. Navid Malik cites “striking data on survival” and “batch manufacturing at low cost” as key elements in DCVax’s “competitive advantage” in the “personalized cancer vaccine revolution.” BETHESDA, MD, June 7, 2010 – Northwest Biotherapeutics, Inc. (“NWBT”) (OTCBB: NWBO), developer of the DCVax® personalized cancer vaccine, today announced the release of a new detailed...
Read More